4-1BBL

September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the filing of a new patent application protecting MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11, for the TCR-T therapy alone as well as in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology to the European Patent Office. MDG2021 marks the second candidate within the KRAS library targeting KRAS G12D (HLA-A*11) for which the Company announced lead selection in June 2024. The addition of MDG2021 to Company’s KRAS targeting TCR library significantly impacts the addressable patient population with the combination of KRAS G12V and KRAS G12D mutations comprising ~50% of all KRAS mutations in all tumors (pan-cancer), or even >70% in pancreatic adenocarcinoma. (Yang et al., J Clin Med 2023) “We are pleased to announce the patent filing for MDG2021, our optimal affinity 3S (sensitive, specific and safe) TCR targeting KRAS G12D (HLA-A*11), alone and in combination with our PD1-41BB armoring and enhancement CSP,” said Selwyn Ho CEO at Medigene. “This filing reaffirms our commitment to broaden our intellectual property for TCRs targeting both neoantigens and cancer testis antigens that have potential utility in multiple TCR-guided treatment modalities including TCR-T therapies such as MDG2021, as well as TCR-guided T cell engager therapies (MDG3010) and TCR-natural killer cell therapies.” Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families worldwide covering applications protecting Medigene’s 3S TCRs as well as its exclusive E2E Platform technologies. Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities, such as T cell receptor engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies for both its in-house product pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is a potential best-in-class, TCR-T therapy to treat multiple solid tumor indications. The End-to-End Platform technologies enable armoring and enhancing of these T cells to overcome the immunosuppressive tumor microenvironment (TME) and ensure the T cell drug product composition maximizes safety, efficacy and durability of response. Medigene’s MDG1015 received IND approval in Q3 2024 and is filing for CTA in Q4 2024. For more information, please visit https://medigene.com/ Medigene’s approach to immunotherapy harnesses the immense power of natural T cell receptors. By combining these TCRs with different components of the immune system such as T cells, natural killer (NK) cells or a CD3 complex (TCE, T cell engager), highly specific, sensitive and safe modalities are formed to either complement and/or activate the body’s defense systems against cancer. Medigene’s comprehensive End-to-End (E2E) Platform is built on a foundation of proprietary and cutting-edge technologies, driving the development of highly specific TCR-guided therapies, including the latest advancements in TCR-T, TCR-NK and TCR-TCE drug products. The E2E Platform incorporates sophisticated TCR generation and optimization techniques, such as Allogeneic-HLA TCR Priming, and integrates advanced product armoring and enhancement features like PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins, and iM-TCR. In addition, the E2E Platform offers solutions to developing optimal cell therapy drug products for improved safety, efficacy and durability. Collaborations with partners like BioNTech, Regeneron and WuXi Biologics further underscore the platform’s capabilities and its potential to revolutionize cancer treatment. This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. The content above comes from the network. if any infringement, please contact us to modify.

23 September 2024 Roquefort Therapeutics plc ("Roquefort Therapeutics" or the "Company") Grant of Japan MK Cell Patent Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, is pleased to announce that the Japan Patent Office has granted the patent for its Mesodermal Killer ("MK") cell therapy. The granting of the MK cell patent by the Japan Patent Office follows the granting of the European patent announced on 2 September 2024, thereby expanding patent protection to the UK, EU and Japan. Novel Cellular Immunology / Oncology Medicine Mesodermal Killer cells are a novel therapeutic cell type developed from the pioneering work of Roquefort Therapeutics' non-executive director, Nobel Laureate, Professor Sir Martin Evans. MK cells display a novel immunophenotype[i] and thus represent a new class of cell, which is confirmed by the granting of patents by the European Patent Office and the Japan Patent Office. The MK cells form an off-the-shelf (allogenic) cellular immunotherapy, with both a direct effect and the ability to recruit and activate Natural Killer ("NK") cells[ii] to modulate an immune response in immunology and oncology indications. Commercial Opportunity in Japan There is a two-fold commercial significance to the granting of the MK cell patent in Japan. Firstly, the Japan patent enables the opportunity to licence the MK cells to Japan Big Pharma companies for the Japan market alone, where the Roquefort Therapeutics' Board has extensive experience of working and partnering (including with Big Pharma companies such as Daiichi Sankyo, Astellas and Chughai). Secondly, the granted Japan patent allows the Company to access an accelerated route-to-market for promising cellular medicines in Japan. The accelerated designation not only speeds up drug development, but also the market approval (MAA) assessment. The attractive benefit package that this designation confers includes market approval granted based on Phase 1 and 2 clinical trials if safety is confirmed[iii]. This may significantly increase the value of cellular medicines as this enables a cheaper and faster route to market. Pre-Clinical Development Since Roquefort Therapeutics acquired the MK cell program as part of the Oncogeni acquisition in 2022, the Company has tested the MK cells in combination with NK cells. MK cells were shown to activate Natural Killer cells and this activation produced up to a two-fold increase in NK efficacy, indicating the potential for MK + NK combination medicines in the high value difficult to treat immunology and oncology disease areas. The Company now plans to complete in vivo studies in preparation for a key value inflection point of initiating a clinical study. This clinical trial may utilise the favourable clinical trial and tax regimes in Japan and Australia to enable faster and cheaper routes to market. Roquefort Therapeutics CEO Ajan Reginald commented: "The granting of this Japan patent for MK cell therapy highlights both the quality of our intellectual property and the novelty of the MK cells together with the enhanced commercial opportunity in Japan. The granted patent creates the opportunity for the Company to out-license the MK cell rights for the territory of Japan to a Japanese Big Pharma company. Japan is the most sophisticated cell therapy market, with a high number of potential partners and an appealing accelerated pathway to market. The Roquefort Therapeutics Board has the personal experience and a strong network from completing deals with Japan Big Pharma. We have initiated these discussions and will update the market in due course" ENDS Roquefort Therapeutics plc +44 (0)20 3918 8633 Stephen West (Chairman) / Ajan Reginald (CEO) SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta +44 (0) 20 3470 0470 Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466 5000 Peak IR (Investor Relations) Seb Wykeham +33 (0)7 44 44 15 42 LEI: ‎254900P4SISIWOR9RH34 About Roquefort Therapeutics Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immunology and oncology markets prior to partnering or selling to big pharma. Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of: · Midkine antibodies with significant in vivo efficacy and toxicology studies; · Midkine RNA therapeutics with novel anti-cancer gene editing action; · Midkine mRNA therapeutics with novel anti-cancer approach; · STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and · MK cell therapy with direct and NK cell-mediated anti-cancer action For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter). [i] which is different from any other cell type including MSCs and includes expression of CD16, CD96, CD112, CD137L, FasL, TRAIL and CD277 and some NK cell [ii] L. Chapman, J. Abdi, S. Galvez-Peisl, A. Keating, Immunophenotypic and functional characterization of Mesodermal Killer (MK) cells: a novel cell type and potential cellular therapy for cancer Cytotherapy, Volume 22, Issue 5, Supplement, 2020, Page S121, ISSN 1465-3249, https://doi.org/10.1016/j.jcyt.2020.03.226. [iii] https://www.tandfonline.com/doi/full/10.1080/14712598.2022.2093637#d1e2011

STUTTGART, Germany I July 29, 2024 I La Merie Publishing released its newest product reviewing the pipeline of drug candidates in research and development of bispecific antibodies targeting PD-L1 and 4-1BB: PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review This product consists of: This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day. 4-1BB (CD137, TNFRSF9) is a costimulatory receptor of the TNF receptor superfamily (TNFRSF) and accumulates on the T-cell surface upon activation. Receptor stimulation by endogenous 4-1BB ligand (4-1BBL) or agonistic 4-1BB antibodies can markedly augment T-cell activation and upregulate inflammatory cytokine response. Agonistic 4-1BB antibodies have exhibited potent anticancer efficacy in a variety of syngeneic mouse models. However, the on-target-off-tumor liver toxicity has hampered the successful clinical development of therapeutic 4-1BB agonists. Programmed death-ligand 1 (PD-L1) also known as CD274 or B7 homolog 1 (B7-H1) is a a 40kDa type 1 transmembrane protein playing a major role in suppressing the adaptive arm of immune systems during particular events. The binding of PD-L1 to the inhibitory checkpoint molecule PD-1 transmits an inhibitory signal which reduces the proliferation of antigen-specific T-cells in lymph nodes, while simultaneously reducing apoptosis in regulatory T cells. PD-L1 is expressed on both hematopoietic and nonhematopoietic cells in tissues. PD-L1 is shown to be highly expressed in a variety of malignancies, particularly lung cancer. One of the most promising next-generation 4-1BB targeting strategies is the use of bispecific antibodies (BsAb) or bispecific fusion proteins, which are designed to be enriched in the tumor microenvironment (TME) enabling tumor cell–mediated 4-1BB activation, thereby minimizing on-target-off-tumor toxicity. Typically, such bispecific proteins are composed of a tumor-associated antigen (TAA)-recognizing arm and a 4-1BB–agonistic arm. A number of PD-L1 x 4-1BB bispecific antibodies are in preclinical and clinical development which were designed to elicit an antitumor response via conditional activation of 4-1BB on T cells and natural killer (NK) cells, which is strictly dependent on simultaneous binding of the PD-L1 arm. The report “ PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review ” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pd-l1-x-4-1bb-cd137-bispecific-antibody-pipeline-review/ About La Merie Publishing La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers. La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest. SOURCE: La Merie Publishing